Omnicell, Inc. (NASDAQ:OMCL) Receives $59.86 Consensus Price Target from Brokerages

by · The Cerbat Gem

Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $58.4286.

Several research firms recently weighed in on OMCL. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. KeyCorp cut their price objective on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Friday. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Wednesday, April 29th.

Check Out Our Latest Stock Analysis on Omnicell

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the period. Millennium Management LLC purchased a new stake in shares of Omnicell during the third quarter valued at $25,625,000. First Light Asset Management LLC purchased a new stake in shares of Omnicell during the first quarter valued at $16,351,000. Boston Partners bought a new position in shares of Omnicell in the fourth quarter worth about $20,805,000. Finally, WCM Investment Management LLC bought a new position in shares of Omnicell in the first quarter worth about $9,783,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 4.7%

OMCL opened at $35.37 on Monday. The firm has a market cap of $1.61 billion, a P/E ratio of 42.11, a P/E/G ratio of 0.96 and a beta of 0.96. Omnicell has a 12 month low of $28.90 and a 12 month high of $55.00. The company has a current ratio of 1.64, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average of $41.97 and a 200 day moving average of $41.09.

Omnicell (NASDAQ:OMCL – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, research analysts forecast that Omnicell will post 1.31 EPS for the current year.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

  • Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
  • Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
  • Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

See Also